ReviewPathogens (Basel, Switzerland)2025
Disarming
Review in Pathogens (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- A secreted AIP-Like peptide fromVirulence · 2026Article
- Staphylococcus aureus-vascular endothelium interactions: Mechanisms and therapeutic opportunities.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- PrfA, the master virulence regulator of Listeria monocytogenes: structural-functional insights, regulatory architecture, and antivirulence strategies.Molecular biology reports · 2026Review
- CutaneousInternational journal of molecular sciences · 2026Review
- A Comprehensive Review of Antimicrobial Peptides and Smart Biomaterials in Chronic Wound Therapy: Overcoming Biofilms, Resistance, and Translational Barriers.International journal of molecular sciences · 2026Review
- Antibacterial and anti-virulence activity of the repurposed agent SX-682 against Staphylococcus aureus.BMC microbiology · 2026Article
- A Genome-Wide Mutant Screen Identifies XopN and XopX as Core Type III Effectors Required for Peach Infection byMicroorganisms · 2026Article
- Multitarget Mechanisms of (‒)‒Epigallocatechin-3-Gallate Against MRSA: From SraP L-Lectin Targeting to Synergistic Antibiotic Effects.Pathogens (Basel, Switzerland) · 2026Article
- A novel SaeS-targeting antivirulence antagonist screened against methicillin-resistantFrontiers in cellular and infection microbiology · 2026Article
- Antibacterial Drug Discovery: Deep Learning Successes and Challenges through the Structural Biology Lens.Computational and structural biotechnology journal · 2026Review
- Betulinic Acid Eradicates Implant-Associated Infections by Disrupting the S. aureus Biofilm Matrix and Potentiating Host Immune Clearance.Microbial biotechnology · 2026Article
- Quorum-Sensing Inhibitors as Potential Antibacterial Agents Against Staphylococcus aureus: A Comprehensive Review.Chemistry & biodiversity · 2026Review
- Attenuation ofAntibiotics (Basel, Switzerland) · 2025Article
- Formulation and characterization of a sortase a inhibitor-loaded PMMA bone cement.RSC advances · 2025Article
- Review
- Biofilm-dispersal patterns in ESKAPE pathogens.Archives of microbiology · 2025Review
- Toxic Shock Syndrome Toxin-1 (TSST-1) inToxins · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.